ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,03
-0,69%
Dow Jones
40 796,94
1,46%
DAX
18 518,03
-0,44%
Brent Oil
83,34
-1,19%
Bitcoin
64 585,66
-0,41%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
12/05/200914h00Business WireAllos Therapeutics to Present at the Eighth Annual JMP Securities Research ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/05/200923h01Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/05/200922h06Edgar (US Regulatory)Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/05/200922h00Business WireAllos Therapeutics Reports First Quarter 2009 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/04/200914h31Edgar (US Regulatory)Amended Annual Report (10-K/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/04/200922h00Business WireAllos Therapeutics to Report First Quarter 2009 Results on May 5, 2009NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/04/200921h00Business WireAllos Therapeutics’ Pralatrexate Demonstrates Anticancer Activity in Multiple Cancer Cell LinesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/04/200914h00Business WireAllos Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2009NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/04/200922h00Business WireAllos Therapeutics Announces Closing of Common Stock OfferingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/04/200922h10Edgar (US Regulatory)Prospectus filed pursuant to Rule 424(b)(5) (424B5)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
31/03/200915h00Business WireAllos Therapeutics Announces Pricing of Common Stock OfferingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
27/03/200922h35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
26/03/200913h00Business WireAllos Therapeutics to Present at the 4th Annual Citi Biotech DayNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
25/03/200913h00Business WireAllos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell L...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/03/200922h30Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/03/200913h00Business WireAllos Therapeutics Appoints David M. Stout to Its Board of DirectorsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/03/200913h00Business WireAllos Therapeutics’ Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Bladder Cancer by the Eu...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/03/200922h00Business WireAllos Therapeutics Reports 2008 ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
26/02/200922h00Business WireAllos Therapeutics to Report 2008 Results on March 3, 2009NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/02/200922h24Edgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/02/200922h49Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/12/200822h00Business WireAllos Therapeutics to Present at the RBC Capital Markets 2008 Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/12/200817h03Business WireAllos Therapeutics Announces Top Line Results from Pivotal Phase 2 PROPEL Trial of Pralatrexate in Patients with Relapsed or ...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/12/200818h30Business WireTwo Pralatrexate Studies Presented at the 50th Annual Meeting of the American Society of HematologyNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/12/200814h00Business WireAllos Therapeutics to Host Analyst and Investor Briefing on Monday, December 8, 2008NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/12/200822h00Business WireU.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/11/200822h00Business WireU.S. FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Diffuse Large B-Cell LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/11/200823h09Edgar (US Regulatory)Amended Current report filing (8-K/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/11/200815h17Business WireFour Pralatrexate (PDX) Studies to Be Presented at the 50th Annual Meeting of the American Society of HematologyNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/11/200822h00Business WireAllos Therapeutics Reports 2008 Third Quarter ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Dernières Valeurs Consultées

EU
EN
Bouygues
NYSE
NKE
Nike
EU
PX1
CAC 40
EU
HO
Thales
EU
SGO
Cie de SaintGobain
FTSE
UKX
FTSE 100
EU
CAP
Capgemini
EU
PX4
SBF 120
NYSE
MRK
Merck
EU
VK
Vallourec
EU
ACA
Credit Agricole
NASDAQ
NVDA
NVIDIA
NYSE
DIS
Walt Disney
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés